Ixekizumab
Common brands: Taltz, Cosentyx, Humira, Methotrexate, Otrexup
Top reporter: Eli Lilly And Company
Interleukin-17A Antagonist [EPC]Tumor Necrosis Factor Blocker [EPC]Folate Analog Metabolic Inhibitor [EPC]Interleukin-23 Antagonist [EPC]Corticosteroid [EPC]
36,303
Total Reports
19,206
Serious Reports
539
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (1.48%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Ixekizumab.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | INJECTION SITE PAIN | 3,866 | |
| 2 | DRUG INEFFECTIVE | 3,217 | |
| 3 | PSORIASIS | 3,205 | |
| 4 | INJECTION SITE ERYTHEMA | 2,178 | |
| 5 | INJECTION SITE REACTION | 1,773 | |
| 6 | INJECTION SITE SWELLING | 1,637 | |
| 7 | INCORRECT DOSE ADMINISTERED | 1,165 | |
| 8 | PRODUCT DOSE OMISSION ISSUE | 940 | |
| 9 | COVID-19 | 920 | |
| 10 | PAIN | 891 | |
| 11 | ARTHRALGIA | 874 | |
| 12 | THERAPY INTERRUPTED | 826 | |
| 13 | DIARRHOEA | 817 | |
| 14 | RASH | 814 | |
| 15 | INJECTION SITE PRURITUS | 788 | |
| 16 | PRURITUS | 787 | |
| 17 | PSORIATIC ARTHROPATHY | 766 | |
| 18 | NAUSEA | 755 | |
| 19 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 673 | |
| 20 | INJECTION SITE URTICARIA | 665 | |
| 21 | FATIGUE | 655 | |
| 22 | NASOPHARYNGITIS | 643 | |
| 23 | INJECTION SITE MASS | 609 | |
| 24 | OFF LABEL USE | 603 | |
| 25 | INJECTION SITE HAEMORRHAGE | 600 | |
| 26 | HEADACHE | 570 | |
| 27 | INJECTION SITE RASH | 537 | |
| 28 | MALAISE | 531 | |
| 29 | URTICARIA | 525 | |
| 30 | INFECTION | 506 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.